Key result
In a nationwide cohort of 908 patients with myxofibrosarcoma, the median overall survival was 155 months with a 5-year survival of 67.7%, and survival outcomes did not improve over time.
Why the study?
Myxofibrosarcoma is a rare mesenchymal soft tissue sarcoma with a high local recurrence rate, but robust epidemiological data are lacking.
What are the prognostic factors and real-life outcomes for patients with myxofibrosarcoma?
Population
908 MFS patients diagnosed between 2002 and 2019 from the Netherlands Cancer Registry
Comparison
Surgery at sarcoma expertise centres vs general hospitals
Design
Nationwide registry-based cohort study
Authors
Loading...
Survival in myxofibrosarcoma has not improved over time; leaves open the impact of expertise-center surgery in observational data.
Cohort (n=908)
Yes
What are the prognostic factors and real-life outcomes for patients with myxofibrosarcoma?
In a large nationwide cohort of myxofibrosarcoma patients, survival outcomes have not improved over time, but surgery at sarcoma expertise centers is associated with better overall survival.
Horst et al. (2022) conducted a cohort in Myxofibrosarcoma (n=908). Myxofibrosarcoma was evaluated on Overall survival. In a nationwide cohort of 908 patients with myxofibrosarcoma, the median overall survival was 155 months with a 5-year survival of 67.7%, and survival outcomes did not improve over time.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: